Skip to content

cAMP Signaling and Muscle Adaptations

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02557581
Enrollment
72
Registered
2015-09-23
Start date
2015-07-31
Completion date
2017-10-31
Last updated
2017-10-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Muscle Hypertrophy in Healthy Young Men

Brief summary

The role of cAMP signaling mediated by beta2-adrenergic stimulation with agonists has been well-studied in skeletal muscles of animals. Studies in humans are scant and the scope of the present study is thus to investigate the role of cAMP signaling by beta2-adrenergic stimulation for muscle adaptations in humans.

Interventions

OTHEREndurance training
OTHERResistance Training
DRUGPlacebo

Sponsors

University of Copenhagen
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
18 Years to 35 Years
Healthy volunteers
Yes

Inclusion criteria

* healthy young men * 18-35 years of age * Informed consent * Active 2-5 hours of training pr. week * Maximal oxygen uptake (ml/min/kg) of 40-60 * Lean body mass of 55-65 kg / Lean mass index 14-22 kg/m2

Exclusion criteria

* Smoker * Allergy towards study drugs * Chronic disease

Design outcomes

Primary

MeasureTime frameDescription
Muscle hypertrophy (lean body mass in Kilograms)2 daysLean body mass (kg) will be measured at two different days by Dual X-ray absorbance (DXA)

Secondary

MeasureTime frameDescription
Energy turnover (ml/min or mmol/kg dry weight muscle)1 dayPulmonary gas exchange and lactate and glycogen will be measured in muscle biopsies obtained before and after intense exercise

Countries

Denmark

Contacts

Primary ContactMorten Hostrup, PhD
mortenhostrup@gmail.com+4524474785

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026